Watch for NMPA approval decisions on sovleplenib NDAs in China (primary ITP and wAIHA) and for any initiation of US clinical development for AIHA. The second orphan designation incrementally strengthens the drug's commercial potential but does not change near-term financials.
HCM drugs
HCM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $14.20entry
- T+1 · 11d ago +6.76%α +6.45% · $15.16
- T+5 · 5d ago +4.58%α +1.29% · $14.85
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
HUTCHMED announced that the US FDA granted Orphan Drug Designation to sovleplenib for autoimmune hemolytic anemia (AIHA), the second such designation for the drug following one for primary ITP in October 2026. The designation provides eligibility for 7 years of US market exclusivity upon approval, tax credits, fee waivers, and regulatory guidance. NDAs for sovleplenib in primary ITP and warm AIHA are under review in China.
Key Facts
- US FDA granted Orphan Drug Designation to sovleplenib for AIHA on November 5, 2026.
- This is the second Orphan Drug Designation for sovleplenib, following one for primary ITP in October 2026.
- Orphan Drug Designation provides 7 years of US market exclusivity upon FDA approval, tax credits, user fee waivers, and regulatory guidance.
- NDAs for sovleplenib in primary ITP and warm AIHA are under regulatory review by China's NMPA.
- HUTCHMED retains all worldwide rights to sovleplenib.
Financial Impact
No financial figures provided; the designation de-risks US regulatory path and extends potential market exclusivity for sovleplenib in a second indication.
Risk Factors
- Orphan Drug Designation does not guarantee FDA approval; clinical development and regulatory review remain uncertain.
- No financial terms or market size estimates for AIHA were disclosed.
- Competing therapies for AIHA may limit commercial uptake even if approved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000076 |
| Document: hcm-20261105x6k.htm | 0001648257-26-000076 |
| Document: 0001648257-26-000076-index-headers.html | 0001648257-26-000076 |
| Document: 0001648257-26-000076-index.html | 0001648257-26-000076 |
| Document: 0001648257-26-000076.txt | 0001648257-26-000076 |
| Earnings Context (Synthetic; results releases only) | 0001648257-26-000076 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Viewing Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers